News Releases

News Category

Year

13 Mar '2020

Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

PRINCETON, N.J. , March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the first quarter ended

PDF Version

03 Mar '2020

Advaxis to Present at the 2020 LD Micro Virtual Conference

PRINCETON, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis will

PDF Version

27 Feb '2020

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response observed in one patient and the other patient achieved stable disease with a 25% reduction in a target

PDF Version

20 Feb '2020

Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on pembrolizumab showed stable disease with a 25% reduction in a site lesion in combination arm PRINCETON, N.J.

PDF Version

13 Feb '2020

Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA ® compared to an estimated 11 months with Standard of Care Median overall survival of 33.7 months in all patients treated with ADXS-PSA in

PDF Version

11 Feb '2020

Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

PRINCETON, N.J. and MENLO PARK, Calif. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer,

PDF Version

30 Jan '2020

Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings

PRINCETON, N.J. , Jan. 30, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the following upcoming presentations at medical meetings: ASCO - Genitourinary Cancers

PDF Version

21 Jan '2020

Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering

PRINCETON, N.J. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into a definitive agreement with two institutional

PDF Version

07 Jan '2020

Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer

ADXS-504 is the Company’s second drug product candidate from the HOT program to receive IND clearance from FDA PRINCETON, N.J. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy

PDF Version